[1]
J. Deprest, A. Ghidini, T. Van Mieghem, D. W. Bianchi, B. Faas, and L. S. Chitty, ‘In case you missed it: the  editors bring you the most significant advances of 2015’, Prenatal Diagnosis, vol. 36, no. 1, pp. 3–9, Jan. 2016, doi: 10.1002/pd.4758.
[2]
N. C. Smith, A. P. M. Smith, and N. C. Smith, Obstetric and gynaecological ultrasound made easy, 2nd ed. Edinburgh: Elsevier Churchill Livingstone, 2006.
[3]
P. P. Pandya, R. Wapner, D. Oepkes, and N. J. Sebire, Eds., Fetal medicine: basic science and clinical practice, Third edition. [London?]: Elsevier, 2020 [Online]. Available: https://www.sciencedirect.com/science/book/9780702069567
[4]
T. W. Sadler, Langman’s medical embryology, Thirteenth edition, International edition. Philadelphia: Wolters Kluwer, 2015.
[5]
‘Baillière’s Clinical Obstetrics and Gynaecology’, vol. 1, no. 3, 1987 [Online]. Available: http://www.sciencedirect.com/science/journal/09503552/1/3
[6]
A. Milunsky and J. M. Milunsky, Eds., Genetic Disorders and the Fetus. Oxford, UK: John Wiley & Sons Ltd., 2021 [Online]. Available: http://doi.wiley.com/10.1002/9781119676980
[7]
J. L. Simpson and S. Elias, Essentials of prenatal diagnosis. New York: Churchill Livingstone, 1993.
[8]
M. R. Harrison, M. S. Golbus, R. A. Filly, and M. R. Harrison, The unborn patient: the art and science of fetal therapy, 3rd ed. Philadelphia: Saunders, 2001.
[9]
P. Chudleigh and B. Thilaganathan, Obstetric ultrasound: how, why and when, 3rd ed. Edinburgh: Elsevier Churchill Livingstone, 2004.
[10]
L. Abramsky and J. Chapple, Prenatal diagnosis: the human side, 2nd ed. Cheltenham, U.K.: Nelson Thornes, 2003.
[11]
International Society for Prenatal Diagnosis, ‘Prenatal diagnosis’, vol. Wiley medical publication [Online]. Available: http://onlinelibrary.wiley.com/journal/10.1002/%28ISSN%291097-0223/issues
[12]
International Fetal Medicine and Surgery Society, ‘Fetal diagnosis and therapy’ [Online]. Available: http://www.karger.com/Journal/Home/224239
[13]
European Society of Human Genetics, ‘European journal of human genetics: EJHG.’ [Online]. Available: http://www.nature.com/ejhg/archive/index.html
[14]
‘Journal of Prenatal Medicine’ [Online]. Available: https://www.degruyter.com/journal/key/jpme/html?lang=en
[15]
‘PloS one’ [Online]. Available: https://journals.plos.org/plosone/
[16]
American Association for Clinical Chemistry, ‘Clinical chemistry’ [Online]. Available: http://www.clinchem.org/content/by/year
[17]
‘Journal of Medical Ethics’, 1975 [Online]. Available: http://www.jstor.org/journal/jmedethics
[18]
Massachusetts Medical Society, ‘The New England journal of medicine’ [Online]. Available: http://www.nejm.org/medical-index
[19]
N. J. Wald and J. P. Bestwick, ‘Performance of antenatal reflex DNA screening for Down’s syndrome’, Journal of Medical Screening, vol. 22, no. 4, pp. 168–174, Dec. 2015, doi: 10.1177/0969141315581005.
[20]
‘nipd_june_2016.pdf’. [Online]. Available: http://www.labs.gosh.nhs.uk/media/764057/nipd_june_2016.pdf
[21]
L. S. Chitty, C. E. van der Schoot, S. Hahn, and N. D. Avent, ‘SAFE—TheSpecial Non-invasiveAdvances inFetal and NeonatalEvaluation Network: aims and achievements’, Prenatal Diagnosis, vol. 28, no. 2, pp. 83–88, Feb. 2008, doi: 10.1002/pd.1929.
[22]
C. F. Wright and H. Burton, ‘The use of cell-free fetal nucleic acids in maternal blood for non-invasive prenatal diagnosis’, Human Reproduction Update, vol. 15, no. 1, pp. 139–151, Oct. 2008, doi: 10.1093/humupd/dmn047.
[23]
M. Hill, A. N. Barrett, H. White, and L. S. Chitty, ‘Uses of cell free fetal DNA in maternal circulation’, Best Practice & Research Clinical Obstetrics & Gynaecology, vol. 26, no. 5, pp. 639–654, Oct. 2012, doi: 10.1016/j.bpobgyn.2012.03.004.
[24]
A. B. Sparks, E. T. Wang, C. A. Struble, and Et al., ‘Selective analysis of cell-free DNA in maternal blood for evaluation of fetal trisomy’, Prenatal Diagnosis, vol. 32, no. 1, pp. 3–9, Jan. 2012, doi: 10.1002/pd.2922.
[25]
A. N. Barrett, T. C. R. McDonnell, K. C. A. Chan, and L. S. Chitty, ‘Digital PCR Analysis of Maternal Plasma for Noninvasive Detection of Sickle Cell Anemia’, Clinical Chemistry, vol. 58, no. 6, pp. 1026–1032, Jun. 2012, doi: 10.1373/clinchem.2011.178939.
[26]
D. W. Bianchi, L. D. Platt, J. D. Goldberg, and Et al., ‘Genome-Wide Fetal Aneuploidy Detection by Maternal Plasma DNA Sequencing’, Obstetrics & Gynecology, vol. 119, no. 5, pp. 890–901, May 2012 [Online]. Available: http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&AN=00006250-201205000-00004&LSLINK=80&D=ovft
[27]
V. Ravitsky, ‘Non-invasive prenatal diagnosis: an ethical imperative’, Nature Reviews Genetics, vol. 10, no. 10, pp. 733–733, Oct. 2009, doi: 10.1038/nrg2631-c1.
[28]
P. A. Benn, ‘Practical and Ethical Considerations of Noninvasive Prenatal Diagnosis’, JAMA, vol. 301, no. 20, May 2009, doi: 10.1001/jama.2009.707.
[29]
Z. Deans, A. J. Clarke, and A. J. Newson, ‘For Your Interest? The Ethical Acceptability of Using Non-Invasive Prenatal Testing to Test “Purely for Information”’, Bioethics, vol. 29, no. 1, pp. 19–25, Jan. 2015, doi: 10.1111/bioe.12125.
[30]
M. Agathokleous, P. Chaveeva, L. C. Y. Poon, and Et al., ‘Meta-analysis of second-trimester markers for trisomy 21’, Ultrasound in Obstetrics & Gynecology, vol. 41, no. 3, pp. 247–261, Mar. 2013, doi: 10.1002/uog.12364.
[31]
E. Celik, M. To, L. C. Y. Poon, and Et al., ‘Cervical length and obstetric history predict spontaneous preterm birth: development and validation of a model to provide individualized risk assessment’, Ultrasound in Obstetrics and Gynecology, vol. 31, no. 5, pp. 549–554, May 2008, doi: 10.1002/uog.5333.
[32]
D. Gallo, L. C. Poon, M. Fernandez, and Et al., ‘Prediction of Preeclampsia by Mean Arterial Pressure at 11-13 and 20-24 Weeks’ Gestation’, Fetal Diagnosis and Therapy, vol. 36, no. 1, pp. 28–37, 2014, doi: 10.1159/000360287.
[33]
D. M. Gallo, L. C. Poon, R. Akolekar, and Et al., ‘Prediction of Preeclampsia by Uterine Artery Doppler at 20-24 Weeks’ Gestation’, Fetal Diagnosis and Therapy, vol. 34, no. 4, pp. 241–247, 2013, doi: 10.1159/000356171.
[34]
K. H. Nicolaides, ‘Turning the Pyramid of Prenatal Care’, Fetal Diagnosis and Therapy, vol. 29, no. 3, pp. 183–196, 2011, doi: 10.1159/000324320.
[35]
A. Syngelaki, T. Chelemen, T. Dagklis, and Et al., ‘Challenges in the diagnosis of fetal non-chromosomal abnormalities at 11-13 weeks’, Prenatal Diagnosis, vol. 31, no. 1, pp. 90–102, Jan. 2011, doi: 10.1002/pd.2642.
[36]
A. Syngelaki, E. Pergament, T. Homfray, and Et al., ‘Replacing the Combined Test by Cell-Free DNA Testing in Screening for Trisomies 21, 18 and 13: Impact on the Diagnosis of Other Chromosomal Abnormalities’, Fetal Diagnosis and Therapy, vol. 35, no. 3, pp. 174–184, 2014, doi: 10.1159/000358388.
[37]
Alessandra Cacciatore, ‘Obstetric management in Rh alloimmunizated pregnancy’, Journal of Prenatal Medicine, vol. 3, no. 2, 2009 [Online]. Available: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3279102/